This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Universitetet I Oslo. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Christoph Driessen: Innovator in Cancer Treatment
Introduction
Christoph Driessen is a notable inventor based in St. Gallen, Switzerland. He has made significant contributions to the field of cancer treatment, particularly through his innovative research on ALK inhibitors. His work focuses on addressing ALK-negative cancers and plasma cell-mediated diseases, which are critical areas in oncology.
Latest Patents
Driessen holds a patent for "ALK inhibitors for treatment of ALK-negative cancer and plasma cell-mediated diseases." This invention provides a method for treating ALK-negative/LTK-positive cancer by administering a pharmaceutically effective dose of a linear inhibitor of ALK. The invention is particularly useful in treating multiple myeloma, including cases that are resistant to proteasome inhibitors. He has 1 patent to his name.
Career Highlights
Christoph Driessen is affiliated with the University of Oslo, where he continues to advance his research in cancer therapies. His work has garnered attention for its potential to improve treatment outcomes for patients suffering from challenging forms of cancer.
Collaborations
Driessen collaborates with esteemed colleagues such as Hesso Farhan and Ludvig Munthe. Their combined expertise contributes to the innovative research being conducted in the field of cancer treatment.
Conclusion
Christoph Driessen's contributions to cancer treatment through his patented innovations highlight the importance of research in developing effective therapies. His work continues to inspire advancements in the medical field.